High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic

BACKGROUND: The WHO-recommended regimen for antiretrovirals (ARVs) is tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV), based on demonstrated superiority of TDF+FTC+EFV over zidovudine (AZT) +FTC+ EFV in clinical trials. However, there are reports of increasing TDF resistance i...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvana, Edsel Maurice, Schwem, Brian, Samonte, Genesis, Telan, Elizabeth, Tactacan-Abrenica, Rosario, Ching, Patrick, Mendoza, Kevin, Arevalo, Geraldine, Alejandria, Marissa, Leyritana, Katerina, Trinidad, Lyka, Penalosa, Christine, Lim, Jodor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631214/
http://dx.doi.org/10.1093/ofid/ofx163.1081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631214/
http://dx.doi.org/10.1093/ofid/ofx163.1081

Ejemplares similares